1.High-throughput sequencing for confirmation of suspected 2019-nCoV infection identified by fluorescence quantitative polymerase chain reaction.
Wen-Da GUAN ; Li-Ping CHEN ; Feng YE ; Dan YE ; Shi-Guan WU ; Hong-Xia ZHOU ; Jia-Yang HE ; Chun-Guang YANG ; Zhi-Qi ZENG ; Yu-Tao WANG ; Run-Feng LI ; Qiu-Ling DU ; Xiao-Li LIANG ; Qin-Hai MA ; Zi-Feng YANG
Chinese Medical Journal 2020;133(11):1385-1386
2.Expression of Glutathione Peroxidases and Its Effect on Clinical Prognosis in Glioma Patients.
Xiao-Mei REN ; Li ZHANG ; Bao XIN ; Wen-Wen QIAN ; Zeng-Run XIA ; Meng QI ; Xiao-Ping DU ; Chuan-Dao SHI ; Qi-Ling LIU ; Rong-Qiang ZHANG
Acta Academiae Medicinae Sinicae 2022;44(2):276-285
Objective To investigate the relationship between the expression of glutathione peroxidase(GPX)genes and the clinical prognosis in glioma patients,and to construct and evaluate the model for predicting the prognosis of glioma. Methods The clinical information and GPX expression of 663 patients,including 153 patients of glioblastoma(GBM)and 510 patients of low-grade glioma(LGG),were obtained from The Cancer Genome Atlas(TCGA)database.The relationship between GPX expression and patient survival was analyzed.The key GPX affecting the prognosis of glioma was screened out by single- and multi-factor Cox's proportional-hazards regression models and validated by least absolute shrinkage and selection operator(Lasso)regression.Finally,we constructed the model for predicting the prognosis of glioma with the screening results and then used concordance index and calibration curve respectively to evaluate the discrimination and calibration of model. Results Compared with those in the control group,the expression levels of GPX1,GPX3,GPX4,GPX7,and GPX8 were up-regulated in glioma patients(all P<0.001).Moreover,the expression levels of other GPX except GPX3 were higher in GBM patients than in LGG patients(all P<0.001).The Kaplan-Meier curves showed that the progression-free survival of GBM with high expression of GPX1(P=0.013)and GPX4(P=0.040),as well as the overall survival,disease-specific survival,and progression-free survival of LGG with high expression of GPX1,GPX7,and GPX8,was shortened(all P<0.001).GPX7 and GPX8 were screened out as the key factors affecting the prognosis of LGG.The results were further used to construct a nomogram model,which suggested GPX7 was the most important variable.The concordance index of the model was 0.843(95%CI=0.809-0.853),and the calibration curve showed that the predicted and actual results had good consistency. Conclusion GPX7 is an independent risk factor affecting the prognosis of LGG,and the nomogram model constructed with it can be used to predict the survival rate of LGG.
Brain Neoplasms
;
Glioblastoma
;
Glioma/diagnosis*
;
Glutathione Peroxidase/metabolism*
;
Humans
;
Peroxidases
;
Prognosis
;
Proportional Hazards Models
3.Efficacy Analysis of MAC Regimen as Salvage Treatment Protocol for Acute Myeloid Leukemia Patients Older Than 55 Years.
Xing-Li ZHAO ; Shu-Ning WEI ; Kai-Qi LIU ; Dong LIN ; Hui WEI ; Ying WANG ; Chun-Lin ZHOU ; Bing-Cheng LIU ; Wei LI ; Zeng CAO ; Ben-Fa GONG ; Yun-Tao LIU ; Xiao-Yuan GONG ; Yan LI ; Run-Xia GU ; Guang-Ji ZHANG ; Jian-Xiang WANG ; Ying-Chang MI
Journal of Experimental Hematology 2015;23(2):396-400
OBJECTIVETo evaluate the efficacy and safety of MAC regimen in the treatment of acute myeloid leukemia(AML) patients older than 55 years.
METHODSA total of 33 relapsed or non-remission AML patients older than 55 years were enrolled in this research. MAC regimen was given as the salvage treatment. Complete remission rate(CR), partial remission rate(PR), overall survival(OS), relapse-free survival(RFS) and adverse effect were analysed.
RESULTSCR rate after the salvage therapy with MAC was 51.1%, partial remission (PR) rate was 6.1%, the overall response rate (ORR) was 57.6%, the median OS was 8 months (1.0-66.0 months), the median relapse-free survival (RFS) was 10.1 months (2.3-40.4 months). Mortality related with salvage treatment in 30 days was 9.1%. Low incidence of severe organ damage were found.
CONCLUSIONMAC can be used as a relative effective and safe regimen for the salvage treatment of the older AML patients.
Antineoplastic Combined Chemotherapy Protocols ; Chlorambucil ; Cytarabine ; Dactinomycin ; Humans ; Leukemia, Myeloid, Acute ; Methotrexate ; Middle Aged ; Recurrence ; Remission Induction ; Salvage Therapy
4.Characteristics of karyotypes and gene mutations for elder acute myeloid leukemia.
Xing-Li ZHAO ; Kai-Qi LIU ; Dong LIN ; Hui WEI ; Ying WANG ; Chun-Lin ZHOU ; Bing-Cheng LIU ; Wei LI ; Cheng-Wen LI ; Qing-Hua LI ; Zeng CAO ; Ben-Fa GONG ; Yun-Tao LIU ; Xiao-Yuan GONG ; Yan LI ; Run-Xia GU ; Ying-Chang MI ; Jian-Xiang WANG
Journal of Experimental Hematology 2015;23(2):300-305
OBJECTIVETo investigate the incidence of karyotypes and gene mutations for elder acute myeloid leukemia and to explore the relationship between each other.
METHODSClinical data and bone marrow samples of elder AML patients were collected. Karyotype and gene mutation (FLT3, NPM1, C-Kit, CEBPα, DNMT3A) test were performed, characteristics of karyotypes and gene mutations were analysed.
RESULTSThe incidence of better risk karyotype was 16.6%, in which the incidences of t(15;17), t(8;21) and inv (16)/t(16;16) were 3.90%, 10.73%, and 1.95% respectively; the incidence of intermediate risk karyotype was 72.2%, in which the incidence of normal karyotype was 57.86%; the incidence of poor risk karyotype was 11.20%, in which the incidence of of MLL/11q23, complex karyotype and monosomal karyotype were 1.95%, 6.34%, 5.85% respectively; the incidences of FLT3, NPM1, C-Kit, CEBPα, DNMT3A mutation were 12.57%, 22.06%, 2.16%, 14.71%, 15.71% respectively. Compared with patients older than 60 years, patients with age of 55-60 years were with less complex karyotype (1.09% vs 10.62%)(P=0.003) and monosomal karyotype (2.17% vs 8.85%)(P=0.032), and more t(8;21)(17.39% vs 5.31%)(P=0.008) and inv (16)/t(16;16)(4.35% vs 0.00%)(P=0.045).
CONCLUSIONFor older AML patients, great difference in the distribution of karyotyes was found between the patients older than 60 years and patients with age of 55-60 years, while no such characteristics was found for gene mutations. Good elucidation of karyotypes and gene mutations are key for the treatment of older acute myeloid leukemia patients.
Humans ; Incidence ; Karyotype ; Karyotyping ; Middle Aged ; Mutation ; Proto-Oncogene Proteins c-kit
5.Expert Consensus for Thermal Ablation of Pulmonary Subsolid Nodules (2021 Edition).
Xin YE ; Weijun FAN ; Zhongmin WANG ; Junjie WANG ; Hui WANG ; Jun WANG ; Chuntang WANG ; Lizhi NIU ; Yong FANG ; Shanzhi GU ; Hui TIAN ; Baodong LIU ; Lou ZHONG ; Yiping ZHUANG ; Jiachang CHI ; Xichao SUN ; Nuo YANG ; Zhigang WEI ; Xiao LI ; Xiaoguang LI ; Yuliang LI ; Chunhai LI ; Yan LI ; Xia YANG ; Wuwei YANG ; Po YANG ; Zhengqiang YANG ; Yueyong XIAO ; Xiaoming SONG ; Kaixian ZHANG ; Shilin CHEN ; Weisheng CHEN ; Zhengyu LIN ; Dianjie LIN ; Zhiqiang MENG ; Xiaojing ZHAO ; Kaiwen HU ; Chen LIU ; Cheng LIU ; Chundong GU ; Dong XU ; Yong HUANG ; Guanghui HUANG ; Zhongmin PENG ; Liang DONG ; Lei JIANG ; Yue HAN ; Qingshi ZENG ; Yong JIN ; Guangyan LEI ; Bo ZHAI ; Hailiang LI ; Jie PAN
Chinese Journal of Lung Cancer 2021;24(5):305-322
"The Expert Group on Tumor Ablation Therapy of Chinese Medical Doctor Association, The Tumor Ablation Committee of Chinese College of Interventionalists, The Society of Tumor Ablation Therapy of Chinese Anti-Cancer Association and The Ablation Expert Committee of the Chinese Society of Clinical Oncology" have organized multidisciplinary experts to formulate the consensus for thermal ablation of pulmonary subsolid nodules or ground-glass nodule (GGN). The expert consensus reviews current literatures and provides clinical practices for thermal ablation of GGN. The main contents include: (1) clinical evaluation of GGN, (2) procedures, indications, contraindications, outcomes evaluation and related complications of thermal ablation for GGN and (3) future development directions.
.